BACKGROUND: Data on infiltrating hepatocellular carcinoma (HCC) are limited. We sought to define treatment and outcome of patients treated with infiltrating HCC compared with patients who had advanced multifocal HCC. METHODS: Between January 2000 and July 2011, a total of 147 patients with advanced HCC were identified from the Johns Hopkins Hospital database (infiltrative, n = 75; multifocal, n = 72). Clinicopathologic data were compared by HCC subtype. RESULTS: Patients with infiltrating HCC had higher alfa-fetoprotein levels (median infiltrative, 326.5 ng/mL vs. multifocal, 27.0 ng/mL) and larger tumors (median size, infiltrating, 9.2 cm vs. multifocal, 5.5 cm) (P < 0.05). Imaging failed to reveal a discrete lesion in 42.7 % of patients with infiltrating HCC. Most infiltrating HCC lesions presented as hypointense on T1-weighted images (55.7 %) and hyperintense on T2-weighted images (80.3 %). Among patients with infiltrating HCC, most (64.0 %) were treated with intra-arterial therapy (IAT), and periprocedural morality was 2.7 %. Patients treated with IAT had longer survival versus patients receiving best support care (median survival, IAT, 12 months vs. best supportive care, 3 months; P = 0.001). Survival after IAT was similar among patients treated with infiltrating HCC versus multifocal HCC (hazard ratio 1.29, 95 % confidence interval 0.82-2.03; P = 0.27). Among infiltrating HCC patients, pretreatment bilirubin >2 mg/dL and alfa-fetoprotein >400 ng/mL were associated with worse survival after IAT (P < 0.05). Patients with progressive disease after IAT had higher risk of death versus patients who had stable/responsive disease (hazard ratio 3.53, 95 % confidence interval 1.49-8.37; P = 0.004). CONCLUSIONS: Patients with infiltrative HCC often present without a discrete lesion on imaging. IAT for infiltrative HCC was safe and was associated with survival comparable to IAT outcomes for patients with multifocal HCC. Infiltrative HCC morphology is not a contraindication to IAT therapy in select patients.
BACKGROUND: Data on infiltrating hepatocellular carcinoma (HCC) are limited. We sought to define treatment and outcome of patients treated with infiltrating HCC compared with patients who had advanced multifocal HCC. METHODS: Between January 2000 and July 2011, a total of 147 patients with advanced HCC were identified from the Johns Hopkins Hospital database (infiltrative, n = 75; multifocal, n = 72). Clinicopathologic data were compared by HCC subtype. RESULTS:Patients with infiltrating HCC had higher alfa-fetoprotein levels (median infiltrative, 326.5 ng/mL vs. multifocal, 27.0 ng/mL) and larger tumors (median size, infiltrating, 9.2 cm vs. multifocal, 5.5 cm) (P < 0.05). Imaging failed to reveal a discrete lesion in 42.7 % of patients with infiltrating HCC. Most infiltrating HCC lesions presented as hypointense on T1-weighted images (55.7 %) and hyperintense on T2-weighted images (80.3 %). Among patients with infiltrating HCC, most (64.0 %) were treated with intra-arterial therapy (IAT), and periprocedural morality was 2.7 %. Patients treated with IAT had longer survival versus patients receiving best support care (median survival, IAT, 12 months vs. best supportive care, 3 months; P = 0.001). Survival after IAT was similar among patients treated with infiltrating HCC versus multifocal HCC (hazard ratio 1.29, 95 % confidence interval 0.82-2.03; P = 0.27). Among infiltrating HCCpatients, pretreatment bilirubin >2 mg/dL and alfa-fetoprotein >400 ng/mL were associated with worse survival after IAT (P < 0.05). Patients with progressive disease after IAT had higher risk of death versus patients who had stable/responsive disease (hazard ratio 3.53, 95 % confidence interval 1.49-8.37; P = 0.004). CONCLUSIONS:Patients with infiltrative HCC often present without a discrete lesion on imaging. IAT for infiltrative HCC was safe and was associated with survival comparable to IAT outcomes for patients with multifocal HCC. Infiltrative HCC morphology is not a contraindication to IAT therapy in select patients.
Authors: M Ebara; M Ohto; T Shinagawa; N Sugiura; K Kimura; S Matsutani; M Morita; H Saisho; Y Tsuchiya; K Okuda Journal: Gastroenterology Date: 1986-02 Impact factor: 22.682
Authors: Aram Demirjian; Peter Peng; Jean-Francois H Geschwind; David Cosgrove; Jacob Schutz; Ihab R Kamel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2011-07-02 Impact factor: 3.452
Authors: Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Juan M Sarmiento; Iwao Ikai; Steven A Curley; David M Nagorney; Jacques Belghiti; Irene Oi-Lin Ng; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2004-11 Impact factor: 3.452
Authors: Richard R Lopez; Shi-Hui Pan; Allen L Hoffman; Carlos Ramirez; Sergio E Rojter; Hector Ramos; Michael McMonigle; Juan Lois Journal: Arch Surg Date: 2002-06
Authors: M Borzio; S Bruno; M Roncalli; G C Mels; G Ramella; F Borzio; G Leandro; E Servida; M Podda Journal: Gastroenterology Date: 1995-03 Impact factor: 22.682
Authors: F Trevisani; P Caraceni; M Bernardi; P E D'Intino; V Arienti; P Amorati; G F Stefanini; G Grazi; A Mazziotti; L Fornalè Journal: Cancer Date: 1993-09-01 Impact factor: 6.860
Authors: Masayuki Kanematsu; Richard C Semelka; Polytimi Leonardou; Maria Mastropasqua; Joseph K T Lee Journal: J Magn Reson Imaging Date: 2003-08 Impact factor: 4.813
Authors: M Cottone; M Turri; M Caltagirone; A Maringhini; E Sciarrino; R Virdone; G Fusco; A Orlando; L Marino; L Pagliaro Journal: Hepatogastroenterology Date: 1988-06
Authors: Jian Zheng; Deborah Kuk; Mithat Gönen; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Ronald P DeMatteo Journal: Ann Surg Oncol Date: 2016-12-05 Impact factor: 5.344
Authors: J Zhang; M N Mavros; D Cosgrove; K Hirose; J M Herman; S Smallwood-Massey; I Kamel; A Gurakar; R Anders; A Cameron; J F H Geschwind; T M Pawlik Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677
Authors: Rohan C Siriwardana; Chandika A H Liyanage; Bhagya Gunetilleke; Madunil A Niriella; Janaka de Silva; Anuradha S Dassanayake; Subani P Jayatunge Journal: Gastrointest Tumors Date: 2017-03-16